SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Windtree Therapeutics Inc. drew increased retail chatter on Tuesday after disclosing plans to adopt a cryptocurrency policy that would enable it to accept digital currencies as payment and hold them as assets.The stock closed at $0.79, up 5% on Tuesday, but declined 4.9% to $0.75 in after-hours trading.The biotech firm said its board approved the development of the policy, which aims to align with broader digital commerce trends.&nbsp;The move comes as the company pursues a transition toward a revenue-generating model.Windtree added that it is in discussions with several groups that focus on Bitcoin and other cryptocurrencies as potential payment options.&nbsp;The company also said it may hold long-term digital assets as part of a broader treasury strategy.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.One user noted increased buying interest in Windtree, citing low float and crypto-related news.&nbsp;<stembedurl>https://stocktwits.com/makedatbread88/message/616696047</stembedurl>Meanwhile, another user expressed skepticism, saying they had never seen a stock that consistently declines.<stembedurl>https://stocktwits.com/Lord_Andrew_London/message/616705134</stembedurl>The stock has declined 95.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representation of Bitcoin, Ripple, Litecoin and Ethereum cryptocurrencies is seen in this illustration photo taken in Krakow, Poland on June 6, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Windtree Stock Falls After-Hours As Board Approves Crypto Policy Amid Revenue Diversification Efforts

The company plans to accept and hold cryptocurrencies and is in talks with several groups focused on digital payments.

Equity

Why Windtree Therapeutics (WINT) Stock Is Volatile Today

Windtree Therapeutics shares are trading lower by 8.6% during Monday's session. The company announced it entered a $1M private placement.
read more...

What's Going On With Windtree Therapeutics Stock?

Windtree Therapeutics shares are racing higher Friday after the company requested the withdrawal of its Registration Statement previously filed with the SEC.
read more...

U.S. stocks rose on Friday morning as investors digested the latest inflation data, which reinforced expectations of a September interest rate cut. The broader market exhibited a mixed performance in the previous session, with early optimism stemming from strong GDP data fading as tech giants dragged down the Nasdaq and S&amp;P 500.Here’s a look at the top three stocks that captured retail investors’ attention ahead of the opening bell today:Windtree Therapeutics Inc (WINT)<figure class="image"><a href="https://stocktwits.com/symbol/WINT"><img style="aspect-ratio:1316/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WINT_sentiment_and_message_volume_score_on_Jul_26_58f5cea25d.png" alt="WINT sentiment and message volume score on Jul 26.png" width="1316" height="320"></a><figcaption>WINT sentiment and message volume score premarket on Jul 26</figcaption></figure>Shares of Windtree Therapeutics surged by an impressive 150% in pre-market trading to reach a high $9.40. The biopharma company announced an update on its novel heart failure treatment, istaroxime, igniting a buying frenzy among retail investors.&nbsp;Stocktwits data revealed overwhelmingly bullish sentiment (71/100), with message volume reaching its highest level this year (90/100). While the stock has experienced a significant decline of over 73% year-to-date, today's surge has injected a dose of optimism among investors.Dexcom Inc (DXCM)In stark contrast to Windtree's performance, Dexcom Inc witnessed a dramatic decline of over 36% in pre-market trading, settling in the mid $60s. The medical device company's disappointing second-quarter revenue results and a weak FY24 revenue guidance for its glucose monitoring devices triggered a sell-off. Despite the price drop, several analysts maintained price targets well above current levels, suggesting potential upside in the long term.&nbsp;However, retail investor sentiment on Stocktwits plummeted to its lowest point this year (10/100), reflecting the bearish outlook, while message volumes reached a 2024 peak (96/100). Concerns about management’s inability to adequately communicate business issues and its plan to fix it, as well as market share impacts from the adoption of GLP-1 weight loss drugs is keeping retail away. &nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DXCM_sentiment_and_message_volume_score_on_Jul_26_17d563e160.png" alt="DXCM sentiment and message volume score on Jul 26.png" width="1324" height="314"></a><figcaption>DXCM sentiment and message volume score premarket on Jul 26</figcaption></figure>Anavex Life Sciences Corporation (AVXL)Shares of Anavex Life Sciences Corporation climbed over 4% in pre-market trading to a high of $7.22, with retail sentiment on Stocktwits at bullish levels (65/100).&nbsp;The neuro-disease-focused biopharma company received a boost from EF Hutton analyst Jason Kolbert, who initiated coverage with a Buy rating and a price target of $46. The analyst highlighted the company's lead therapy, ANAVEX2-73, for Alzheimer's Disease (AD), which is on track for regulatory submission by the end of the year. The potential market for ANAVEX2-73, coupled with its broader therapeutic applications, has fueled investor optimism.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_on_Jul_26_d22a8e0bab.png" alt="AVXL sentiment and message volume score on Jul 26.png" width="1320" height="312"></a><figcaption>AVXL sentiment and message volume score premarket on Jul 26</figcaption></figure><a href="https://www.vecteezy.com/photo/29286690-ai-generative-business-man-standing-in-the-stock-market-realistic-image-ultra-hd-high-design-very-detailed">Photo</a> courtesy of syedqaseem on Vecteezy

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Before the Bell

Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. 

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Premarket

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 08/04/2024

Gagnants
L'action Kineta (NASDAQ:KA) a mont lundi de 16,77% 0,63 dollars lors de la session after-market.
Le titre Windtree Therapeutics (NASDAQ:WINT) a mont de 14,63% 0,47 dollars.
Le titre...

Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 56.0% in February

Windtree Therapeutics, Inc. (NASDAQ:WINT  Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling...

Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT  Get Free Report) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 101,100...

Windtree Therapeutics files to sell 608,272 shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Windtree Therapeutics   This Biotech Inks License Deal For Lead Candidate

Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga.
Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in...

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

WARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15...

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Windtree Therapeutics Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$0.0936
Prev Close	$0.10
Open	$0.10
Dividend Yield	0.00%
50-Day Moving Average	$0.0976
Beta	1.45
Avg. Volume	510,751.90
PE Ratio	0.00

52-Week High	$37.42
52-Week Low	$0.058
Market Capitalization	$2.93M
EPS (Annual)	-$104.35
Price to Book	0.26
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

WINT
Windtree Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest WINT News

WINTWindtree Therapeutics Inc